dadstimeon Posted April 7, 2006 Share Posted April 7, 2006 http://feed.insnews.org/v-cgi/feeds.cgi ... id=1746805 Apr 07, 12:22 PM Quebec firm Ecopia BioSciences has began dosing its first patient in a phase I clinical trial of its anticancer product candidate ECO-4601. The phase I study is designed to test the safety and tolerability of ECO-4601. Up to 30 patients suffering from one of six types of cancer, and who are refractory to current chemotherapies, will be recruited for this trial. Such cancers include glioblastomas, breast, prostate, ovarian, lung and colon cancers. The clinical trial involves a 21-day cycle during which escalating dosages of the compound will be tested in different patients via continuous infusion using ambulatory pumps for 14 days, followed by a seven-day rest. The investigation is taking place at the clinical research unit of the Sir Mortimer B. Davis - Jewish General Hospital (JGH), a McGill University Teaching Hospital. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class, which, according to Ecopia, is the fruit of a very unique drug discovery platform called the Decipher technology. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.